cphi-onlineJanuary 24, 2017
Tag: Orphan Drug , cystic fibrosis
Topline results from the Phase II trial are expected by year-end 2017.
FDA has granted orphan drug designation for Convert Pharmaceuticals' CTP-656, Concert’s next generation CFTR potentiator being developed for the treatment of cystic fibrosis (CF). In December 2016, Concert initiated a Phase II trial in the US evaluating CTP-656 in CF patients with gating mutations. Topline results from the Phase II trial are expected by year-end 2017.
"Receiving orphan drug designation is an important regulatory milestone, and we are pleased that CTP-656 for cystic fibrosis has been granted this status," said Roger Tung, President and Chief Executive Officer of Concert Pharmaceuticals. "We are developing CTP-656 to potentially offer advantages over standard of care, and our team is committed to advancing the clinical development program to address the unmet needs of individuals with CF."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: